Scottish Hyperacute stroke Activity

Register and Evaluation (SHARE)

Peter Langhorne

University of Glasgow

What’s in a name?

S – Scottish

H - Hyperacute

A – Assessment and

M - Management

E - Evaluation

What’s in a name?

S – Scottish

H - Hyperacute

I - Investigation and

T - Treatment

E - Evaluation

What’s in a name?

S – Scottish

H – Hyperacute stroke

A – Activity

R – Register and

E - Evaluation

Stroke in Scotland

• Over 10,000 people have a new stroke each year

• 70,000 Scots living with consequences of a stroke

• Average lifetime cost of stroke £45,000

• Good progress in developing services

• SSCA has help drive up standards

Before After

Thrombolysis in acute stroke

In 2002, European Union regulatory authority approved rt-PA for stroke CONDITIONALLY

• Age 18-80

• In high quality stroke centres with stroke units with certain monitoring requirements

• Within 3 hours of anischaemic stroke

Time is Brain

Saver, Stroke 2006

0 2 4 6

30

20

10

0

Number making full recovery per 100 treated

Impact of thrombolysis

Time (hours)

Benefit

Haemorrhage into an infarct

Saver, Stroke 2006

0 2 4 6

30

20

10

0

Number making full recovery per 100 treated

Impact of thrombolysis

Time (hours)

Benefit

Harm

Time is Brain

Inclusion criteria

• Clinical symptoms and signs of definite acute stroke

• Clear time of onset• Presentation within 3 hrs of acute onset• Haemorrhage excluded by CT scan• Age 18 - 80 years old • NIHSS less than 25• Consent to treat (every effort must be made to

contact next of kin)

• Rapidly improving or minor stroke symptoms• Stroke or serious head injury 3 months• Major surgery, obstetrical delivery, external heart

massage last 14 days, • Seizure at onset of stroke• Prior stroke and concomitant diabetes• Severe haemorrhage last 21/7• Increase bleeding risk• History of central nervous damage (neoplasm,

haemorrhage, aneurysm, spinal or intracranial surgery or haemorrhagic retinopathy)

• Symptoms suggestive of SAH (even if CT is normal)• *Blood pressure above 185 mmHg systolic or 110

mmHg diastolic • Known clotting disorder• Patient on heparin or warfarin• Suspected iron deficient anaemia or thrombocytopenia• Suspected hypoglycaemia or hyper glycaemia >3

mmol/l > 22 mmol/l• Bacterial endocarditis, pericarditis• Acute pancreatitis• Premorbid dependency

• Ulcerative GI disease last 3 months, oesophageal varices, arterial-aneurysm, arterial/venous malformation.

• Severe liver disease including cirrhosis, acute hepatitis

• Neoplasm with increased bleeding risk • Large hypodensity on CT scan (use ASPECTS*

scoring if time permits; otherwise use the 1/3 of MCA territory rule)

• Symptoms suggestive of SAH (even if CT is normal)

• *Blood pressure above 185 mmHg systolic or 110 mmHg diastolic

• Known clotting disorder• Patient on heparin or warfarin• Suspected iron deficient anaemia or

thrombocytopenia• Suspected hypoglycaemia or hyper glycaemia >3

mmol/l > 22 mmol/l• Bacterial endocarditis, pericarditis• Acute pancreatitis• Premorbid dependency • Ulcerative GI disease last 3 months, oesophageal

varices, arterial-aneurysm, arterial/venous malformation.

Exclusion criteria

Low densityloss of grey/white definitionloss of insulaloss of basal ganglia

Swellingloss of sulci

effacement of ventricles

Hyperdense artery

Farrall, Kane, Wardlaw

Conditions

• Acute stroke unit• Under the care of stroke physician or

neurologist• Monitored bed• Nurses trained in thrombolysis & acute

skills• Protocols & guidelines for care• Access to immediate imaging (24hrs)

CT head scanning availability

Hyperacute stroke specialist teams

Patient has Video Consultation with the consultant following viewing of CT brain image

-

Network of acute sites (with CT scanning) and stroke specialists

Use of rt-PA for acute ischaemic stroke ‘within licence’ in Europe (SITS-MOST registry 2007)

0

50

100

150

200

250

rt-

PA

fo

r s

tro

ke p

er m

illi

on

po

p'n

FinlandSwedenAustriaNorwayCzech RepublicSloveniaBelgiumDenmarkSpainIcelandGermanyPortugalItalySlovakiaAustraliaNetherlandsUnited KingdomLithuaniaPolandFranceGreeceCroatiaHungaryRussia

SITS-MOST 29/1/2007

SITS Register• Section• Data itemBaselineTreatment file namePostcodeCHI

numberAgeGenderSITS-MOST patientDate/time stroke onsetDate/time arrival 1st hospitalDate/time arrival Rx hospitalDate/time brain imaging examDate/time brain imaging reportDate/time of rt-PA treatmentRankin before strokeHypertensionDiabetesHyperlipidaemiaCurrent smokerPrevious smokerPrevious diagnosis of strokeAtrial fib (incl. Paroxysmal)Congestive heart failureNumber of risk factorsAspirin at stroke onsetDipyridamole at stroke onsetClopidogrel at stroke onsetOther antiplatelet at stroke onsetAnticoagulants, high doseAnticoagulants, low doseAnticoagulants, oralAntihypertensive at stroke onsetAntihypertensive oralGlucose before treatmentTotal serum cholesterol level within 24h of stroke onsetCurrently partic. In stroke RCTMethod of consultation [a]Brain imaging review [b]ADRCause of ADR is reasonable related to Actilyse treatmentType of ADRDate SADR faxed to BIIntensity of ADRDate/time of onset of ADRSpecify reaction [c]Treatment file nameSITS-MOST patientAgeGenderCause of ADR is reasonable related to Actilyse treatmentType of ADRDate SADR faxed to BIIntensity of ADRCriteria of serious ADRDate/time of onset of ADRSpecify reactionSerious AD report form

• DeathTreatment file nameSITS-MOST patientAgeGenderDate of deathPrimary cause of deathCause of death reasonable related to Actilyse treatmentAdd. info. related to deathSerious AD report formNIH stroke scale - BeforeNIH done – before treatmentIf NIH done – total scoreSystolic BPDiastolic BPNIH items 1-11NIH total (calculated)NIH stroke scale – At 2hNIH done – at 2hSystolic BPDiastolic BPNIH items 1-11NIH total (calculated)NIH stroke scale – At 24hNIH done – at 24hSystolic BPDiastolic BPNIH items 1-11NIH total (calculated)NIH stroke scale – At 7dNIH done – at 7dSystolic BPDiastolic BPNIH items 1-11NIH total (calculated)ImagingCT doneCT date/timeCT current infarctCT dense artery signCTA occlusion (optional)CT perfusion deficit (optional)CT perfusion deficit volume optCT infarct volume (optional)CT perfusion/infarct mismatch (optional)CT local haemorrhageCT remote haemorrhageCT volume PH2CT cerebral oedemaMR doneMR date/timeMR current infarctMR artery occlusionMR perfusion deficit (optional)MR diffusion volume (optional)MR perfusion/infarct mismatch (optional)MR local haemorrhageMR remote haemorrhageMR volume PH2MR cerebral oedemaBrain Imaging result [d]TCD occlusionTCD date/timeTreatmentTreatment file nameSITS-MOST patientAgeGenderHas patient received treatment with ActilyseDose mgEstimated weight (kilos)Measured weight (kilos)Reason why no treatment was given [e]Full dose given (0.9mg/kg)Reason why full dose was not given24hTreatment file nameSITS-MOST patientAgeGenderGlobal outcome 24h after start of rt-PA treatment [f]DischargeTreatment file nameSITS-MOST patientAgeGenderAspirin since admissionDipyridamol since admissionClopidogrel since admissionOther antiplatelet since admissionAnticoagulants, high doseAnticoagulants, low doseAnticoagulants, oralAntihypertensive, ivAntihypertensive, oralI-national class of diseases(ICD)Repeat brain imaging done [g]Repeat brain imaging result [h]Global outcome on discharge /7dGlobal outcome on discharge /7d [i] ?Total serum cholesterol level at 7 days of stroke onset, mg/dl3 month follow upTreatment file nameSITS-MOST patientAgeGenderRankin 3m months (+/- 10 days)

SHARE project

Prospective part• Basic common dataset in

SSCA

• Numbers treated

• Contraindications

• Time to treatment

• Complications

• Outcomes

• Equity/service issues

Retrospective part• Jan 2008 – present

• Multiple local audits

• Compile basic common dataset

• Same data as SSCA

• Same outcomes and analysis

• Centralised resource

SHARE project

Prospective part• Basic common dataset in

SSCA

• Numbers treated

• Contraindications

• Time to treatment

• Complications

• Outcomes

• Equity/service issues

Retrospective part• Jan 2008 – present

• Multiple local audits

• Compile basic common dataset

• Same data as SSCA

• Same outcomes and analysis

• Centralised resource

Section Data item Details

Patient details Date/time arrival at treating hospital

Date/time brain imaging exam

Date/time of rt-PA treatment

If not given, reason why no treatment was given

Too late, medical contraindication, radiological contraindication, other.

Process Method of consultant consultation Face-to-face, videoconference, telephone, other

Brain imaging review Stroke consultant, radiologist, other

Brain Imaging result

NIH stroke scale NIH done – before treatment

If NIH done – total score NIHSS

Discharge

Repeat imaging Repeat brain imaging done yes/ no

Date of repeat imaging

Repeat brain imaging result normal, infarct, haemorrhage, other

Adverse reaction (ADR)

ADR occurred - reasonably related to Actilyse treatment

Anaphylaxis, symptomatic intracranial haemorrhage, other haemorrhage, other

Date of ADR

Outcome Function Rankin score

3 Month Function Rankin score (optional?)

• Promising treatment for a minority of stroke patients

• National and international guidelines NICE technology appraisal

• Features in Scottish and English stroke strategies• Challenge to deliver in practical and equitable

manner• Need to monitor developments in Scotland

The promise and challenge of thrombolysis for ischaemic stroke